Targeting Polyamines using DFMO in Persons with Type 1 Diabetes: A Randomized Double-Masked Placebo-Controlled Phase I/II Study to Evaluate the Safety Tolerability and Initial Pharmacodynamics of Multiple Ascending Doses

L
Linda DiMeglio, MD

Primary Investigator

Overview

The purpose of this study is to determine if different doses of a drug known as DFMO have an effect on reducing the amount of stress that is experienced by the body's beta cells and preserves residual c-peptide.

Description

The purpose of this study is to determine if different doses of a drug known as DFMO have an effect on reducing the amount of stress that is experienced by the body's beta cells and preserves residual c-peptide.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    type 1 diabetes
  • Age: Between 12 Years - 40 Years
  • Gender: All

Inclusion Criteria
Clinical diagnosis of type 1 diabetes within 2-8 months
Normal hearing
Exclusion Criteria
Presence of severe, active disease that interferes with dietary intake or requires the use of chronic medication, with exception of well-controlled hypothyroidism and mild asthma not requiring oral steroids
Diabetes other than T1D
Chronic illness known to affect glucose metabolism
Inability to swallow pills
Psychiatric impairment or current use of anti-psychotic medication
Hematologic abnormalities
Impaired renal function
Pregnant

Additional Information:
Participants will be paid for their participation.

Updated on 20 Nov 2022. Study ID: 1411735324

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center